Roles of the WHHL Rabbit in Translational Research on Hypercholesterolemia and Cardiovascular Diseases by Kobayashi, Tsutomu et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2011, Article ID 406473, 10 pages
doi:10.1155/2011/406473
Review Article
Roles oftheWHHL Rabbitin TranslationalResearch on
Hypercholesterolemia and CardiovascularDiseases
TsutomuKobayashi,1 Takashi Ito,1 and Masashi Shiomi1,2
1Institute for Experimental Animals, Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku,
Kobe 650-0017, Japan
2Section of Animal Models for Cardiovascular Disease, Division of Cardiovascular Medicine,
Kobe University Graduate School of Medicine, 7-5-1, Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan
Correspondence should be addressed to Masashi Shiomi, ieakusm@med.kobe-u.ac.jp
Received 10 September 2010; Revised 17 January 2011; Accepted 15 February 2011
Academic Editor: Andrea Vecchione
Copyright © 2011 Tsutomu Kobayashi et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Conquering cardiovascular diseases is oneofthe mostimportantproblems inhumanhealth. To overcome cardiovascular diseases,
animal models have played important roles. Although the prevalence of genetically modiﬁed animals, particularly mice and rats,
hascontributed greatlytobiomedicalresearch, notallhumandiseasescanbeinvestigated inthisway.Inthestudyofcardiovascular
diseases, mice and rats are inappropriate because of marked diﬀerences in lipoprotein metabolism, pathophysiological ﬁndings of
atherosclerosis,andcardiacfunction.Ontheotherhand,sincelipoproteinmetabolismandatheroscleroticlesionsinrabbitsclosely
resemble thoseinhumans,severaluseful animalmodels forthese diseases havebeen developed inrabbits.Oneofthe mostfamous
of these is the Watanabe heritable hyperlipidemic (WHHL) rabbit, which develops hypercholesterolemia and atherosclerosis
spontaneously due to genetic and functional deﬁciencies of the low-density lipoprotein (LDL) receptor. The WHHL rabbit has
been improved to develop myocardial infarction, and the new strain was designated the myocardial infarction-prone WHHL
(WHHLMI) rabbit. This review summarizes the importance of selecting animal species for translational research in biomedical
science, the development of WHHL and WHHLMI rabbits, their application to the development of hypocholesterolemic and/or
antiatherosclerotic drugs, and future prospects regarding WHHL and WHHLMI rabbits.
1.Introduction
AccordingtoWHO,themajor causeofdeathwithin member
nations is cardiovascular diseases which account for about
30% of all deaths [1]. This report has indicated that cardio-
vascular diseases are one of the most important classes of
diseasestobeovercome.Asmainriskfactorsforcardiovascu-
lardiseases,hypercholesterolemia,hypertension, disordersin
glucosemetabolism, smoking, aging, male gender, and social
stress are listed. Particularly, control of serum lipid levels is
thought to be most important for the prevention of cardio-
vascular diseases. Currently, in the Japanese population, the
upper limits of the normal ranges for serum total cholesterol
and LDL cholesterol levels are 220mg/dL and 140mg/dL,
respectively, and the lower limit of the normal range of
HDL cholesterol is deﬁned as 40mg/dL [2]. According to
studies conducted during the 1980s, the incidence of car-
diovascular events increases as the serum cholesterol level
increases and decreases with hypocholesterolemic treat-
ments [3]. One potent hypocholesterolemic compound is
statin, acompetitiveinhibitorof3-hydroxy-3-methylglutaryl
(HMG)-CoAreductase,arate-limitingenzymeincholesterol
synthesis. The ﬁrststatin(compactin)wasinitially developed
by a Japanese pharmaceutical company, Sankyo Co. Ltd.
[4], and this accelerated the development of cholesterol
loweringdrugs.Thehypocholesterolemiceﬀectofcompactin
was initially examined with rats. However, the anticipated
cholesterol-lowering eﬀect was not observed [5], and the
development of this compound was ceased. On the other
hand, since compactin showed a potent inhibitory eﬀect on
cholesterol synthesis in vitro and in chickens, researchers had
been looking for other mammalian species applicable for2 Journal of Biomedicine and Biotechnology
theassessment of this agent.They found a report of a mutant
rabbit strain showing hyperlipidemia, written in a Japanese
university’s bulletin [6]. This rabbit strain contributed
greatly to the developmentof this compound. The strain was
theWatanabe heritablehyperlipidemic(WHHL)rabbit.This
was in 1979. Currently, there are seven statins in widespread
clinical use. It is estimated that statins are prescribed to more
than 40 million patients worldwide and statin therapy has
decreased mortality from cardiovascular diseases by 20–50%
[7]. Thus statins became essential agents for the treatment
of hypercholesterolemia and cardiovascular diseases. These
results demonstrate the importance of selecting animal
species and/or animal models for translational research to
develop therapeutic agents.
This review raises the importance of selecting animal
species and/or animal models for translational research by
describing the history of the WHHL rabbit and its contribu-
tion to studies of hypercholesterolemia and atherosclerosis.
2.The Developmentofthe WHHL Rabbit
and ItsCharacteristics
The history and characteristics of the WHHL rabbit were
described in a previous article [8]. In 1973, Dr. Yoshio
Watanabe (1927–2008) found one male Japanese white
rabbit showing hyperlipidemia. From this mutant, he estab-
lished a strain, the WHHL rabbit, after seven years of
selective breeding. At ﬁrst, this strain was designated the
hyperlipidemic rabbit (HLR) [9]. He submitted a study on
this strain to an international journal and renamed it the
Watanabe heritable hyperlipidemic (WHHL) rabbit [10],
according to a suggestion by the editor.
The strain has 300–700mg/dL of total cholesterol and
300–400mg/dL of triglyceride in plasma. There were athe-
rosclerotic lesions in the aorta and xanthoma in the digital
joints. The serum glucose level and blood pressure were
in normal ranges. In WHHL rabbits, the function of low-
density lipoprotein (LDL) receptors on the cell membrane
was almost deﬁcient and the clearance of LDL from the
circulation delayed [11]. Such symptoms closely resemble
human familial hypercholesterolemia (FH), which develops
spontaneously, and thus the WHHL rabbit is recognized
as the ﬁrst animal model of this disease. Later, the Nobel
Prize winners Goldstein and Brown used WHHL rabbits to
verify their hypothesis of an LDL receptor pathway for the
metabolism of lipoproteins and clariﬁed human lipoprotein
metabolism [12–15]. Their studies revealed that lipoprotein
metabolism in the WHHL rabbit closely resembles human
FH. Consequently, WHHL rabbits were used as an animal
model for the development of cholesterol-lowering agents.
O n eo ft h em o s ti m p o r t a n tf e a t u r e so fa na n i m a lm o d e l
for hyperlipidemia is the occurrence of myocardial infarc-
tion, the ﬁnal event of human hypercholesterolemia. The
developmentof severeatheroscleroticlesions in the coronary
arteries is a prerequisite for the occurrence of myocardial
infarction, but the incidence of coronary atherosclerosis in
the WHHL rabbit was initially very low. To establish a
new strain which develops coronary atherosclerosis, serial
selective breeding was conducted and in 1985, the coronary
atherosclerosis-prone WHHL rabbit was developed [16].
Further, a strain with severe coronary atherosclerosis was
developed in 1992 [17]. Despite such long-term eﬀorts, the
incidence of myocardial infarction remained very low. After
a further seven years of selective breeding with improved
criteria, such as the use of descendents of rabbits with ma-
crophage-rich coronary lesions, a new strain of WHHL
rabbits was established; the myocardial infarction-prone
WHHL (WHHLMI) rabbit that spontaneously develops
myocardial infarction by progression of coronary atheroscle-
rosis followed by occlusion of the coronary arteries [18].
The characteristics of WHHLMI rabbits are described in a
previous review [19]. During their establishment, marked
diﬀerences in the composition of atherosclerotic plaques
were found between the aorta and coronary arteries [20],
and the WHHLMI rabbit became an animal model with
which to examine the inhibitory eﬀectsof drugs on coronary
atherosclerosis. These studies suggested genetic factors other
than hypercholesterolemia to be important to myocardial
infarction and coronary atherosclerosis.
Figure 1 s h o w st h ec h a n g e si ns e r u ml i p i dl e v e l sw i t h
aging and the distribution of cholesterol in lipoproteins
among WHHLMI rabbits [8]. Serum cholesterol levels are
900–1,400mg/dLatweaning (3monthsold)andat6months
old, and then decrease gradually (700–1,200mg/dL at 12
months old, 600–1,100mg/dL at 18 months old, and 500–
1,000mg/dL at 24 months old). Serum triglyceride levels
are 150–500mg/dL and the change with aging is small. The
HMG Co-A reductase activity (cholesterol biosynthesis) in
WHHLMI rabbits does not decrease with aging and the
precise mechanism of the age-related decrease in cholesterol
is still unknown [21]. About 70% of cholesterol occurs in
the LDL fraction, 16% in the very low-density lipoprotein
(VLDL) fraction, 13% in the intermediate density lipoprote-
in (IDL) fraction, and 0.8% in the high density lipoprotein
(HDL) fraction. Figure 2 shows the extent of atherosclerotic
lesions in the coronary arteries and aorta of WHHLMI
rabbits [8]. The main coronary artery is the left circumﬂex
artery and the atherosclerotic lesion is more progressed
compared to that in the left anterior descending artery and
the right coronary artery. Therefore, the degree of coronary
atherosclerosis (cross-sectional narrowing) has been evalu-
ated using the left circumﬂex artery. The degree of aortic
atherosclerosis was shown as the ratio of the surface lesion
area to the lumen surface area of the aorta. Atherosclerotic
lesions develop from 2 months old. At age 12 months,
coronary cross-sectional narrowing was about 80% and
about60%oftheaorticlumensurfacewascoveredbyathero-
sclerotic lesions. At 18 months old, coronary cross-sectional
narrowing and aortic lesion increased to 90% and 80%,
respectively [22].
Prior to the development of the WHHLMI strain,
WHHL rabbits were used to investigate mechanisms of the
development of atherosclerosis, and many aspects have been
clariﬁed:accumulationofoxidizedLDLintheatherosclerotic
lesions [23, 24]; antiatherosclerotic eﬀects of antioxidants
(inhibition of oxidized-LDL formation) [25, 26]; the expres-
sion of monocyte adhesion molecules on arterial endothelialJournal of Biomedicine and Biotechnology 3
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Figure 1: Changes in the serum lipid levels of WHHLMI rabbits with age (a), and the distribution of cholesterol in lipoproteins (b). Data
are represented as the mean ± standard error of the mean. The serum cholesterol levels at 12 months old were about 900mg/dL. Excess LDL
cholesterol is atherogenic andHDL hasantiatherogenic function. In WHHL rabbits, LDL is accumulated in the plasmaandHDL-cholesterol
is low, less than 20mg/dL. The serum cholesterol levels decrease gradually with aging.
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Figure 2: Development of atherosclerotic lesions in WHHLMI
rabbits with age. The solid line denotes the degree of coronary
atherosclerosisshownas coronarycross-sectionalnarrowing;lesion
areas/area surrounded by the internal elastic lamina ×100 (%). The
dotted line denotes the degree of aortic atherosclerosis; sum of the
surface areas of the lesion/total surface area of the aortic lumen
×100 (%). Modiﬁed from Shiomiand Ito [8].
cells at the initiation of atherosclerosis [27]; scavenging of
oxidized LDL at the lesions by macrophages through the
scavengerreceptors,VLDLreceptors, andremnant receptors;
accumulation of form cells derived from macrophages
in arterial intima followed by further development of
atherosclerotic lesions [28–32].
3.SpeciesDifferencesinLipidMetabolism
and Atherosclerosis
As mentioned, lipoprotein metabolism in rabbits closely
resembles that in humans. However, representative labo-
ratory animals such as mice and rats have very diﬀerent
lipoproteinmetabolismfromthatinhumans(Table 1).Some
examplesofmajorspeciesdiﬀerencesin lipidmetabolismare
the following. (1) In mice and rats, apoB editing enzyme is
observed in the intestine and in the liver, but in humans and
rabbits, this enzyme is expressed only in the intestine [33].
In humans and rabbits, apoB-48 is a major apolipoprotein
of chylomicron and chylomicron remnants, which carry
exogenous lipids derived from foods and apoB100 is a
major apolipoprotein of VLDL, IDL, and LDL, which are
endogenous lipoproteins derived from liver. In mice and
rats, however, endogenous lipoproteins as well as exogenous
lipoproteins also contain apoB-48, because of the expression
of apoB editing enzyme in the liver [34]. Since the metabolic
clearance of lipoproteins containing apoB-48 is very rapid,
apoB-48 containing VLDL particles disappear rapidly from
the circulation in mice and rats. As a result, the LDL lipid
levels in mice and rats are very low compared with those
in humans. (2) Hepatic lipase is circulating in the blood
stream in mice thusdiﬀerentfrom humans indegradation of
neutral lipids and transportation of free fatty acids into the
tissues [35].(3) In mice and rats, there is no cholesterol-ester
transfer protein (CETP) activity in plasma, which transfers
cholesterolfromHDLtoVLDL,IDL,andLDL[36],although
CETP plays an important role in humans and rabbits. As
a result, in mice and rats, the proportion of cholesterol in
the HDL fraction is high compared with other lipoprotein
fractions. Therefore, lipoprotein proﬁles of mice and rats are
markedly diﬀerent from that of humans, even in knockout
mice lacking apoE or the LDL-receptors [8]. (4) Competitive
inhibitors ofa rate-limiting enzyme for cholesterol synthesis,
statins,showedpotenthypocholesterolemiceﬀectsinWHHL
rabbits [37–45] but not in mice and rats [5]. In humans,
statins are the most eﬀective hypocholesterolemic drugs.
These results demonstrate how it is important to choose
appropriate species in translational research. (5) C-reactive4 Journal of Biomedicine and Biotechnology
Table 1: Comparison of lipid metabolism, atherosclerosis,and cardiac functions between genetically modiﬁed mice and WHHLMI rabbits.
Genetically modiﬁed mice WHHLMI rabbits
Lipid metabolism
Major lipoprotein in the blood X (Chylomicron, VLDL) O (LDL)
Structural protein in theendogenous lipoprotein X (apoB48) O (apoB100)
Expression of apoB editing enzyme X (The small intestine, liver) O (The small intestine)
CETP activity in the blood X (No) O (Exists)
Hepatic lipase X (Released to circulation) O (Bound to vessel membrane)
Atherosclerosis
The coronary lesion X (Resistant) Δ (Spontaneously develops)
Composition of the lesions X (Over accumulation of macrophages) O (Various lesions)
VLDL receptor X (no expression) O (expression)
Heart
Electrocardiogram
Limb lead X (Largely diﬀerent waveforms) O (Similar to humans)
Chest lead X (Diﬃcult to monitor) O (Similar to humans)
Myocardial ion channel X (Ito and IK,slow)O ( I kr and IKs)
Myocardial ﬁbers X (α-myosin heavy chain) O (β-myosin heavy chain)
Others
Inﬂammatory markers X (SAP) O (CRP)
The hypocholesterolemic eﬀect of statins X (Resistant) O (Eﬀective)
O: similar to humans; Δ: partly similar to humans; X: largely diﬀerent from humans.
protein (CRP), a major inﬂammatory marker in humans
and rabbits, which increases in patients with acute coronary
syndrome [46], is not responsive to inﬂammation in mice
and rats, due to a lack of complement activation [47].
The major inﬂammatory marker of mice is serum amyloid
P component (SAP), instead of CRP. (6) The types of
myocardial ﬁbers in mice are also diﬀerent from those of
humans and rabbits [48]. (7) Moreover, the ECG waveforms
in mice and rats are clearly diﬀerent from those of humans,
b u tr a b b i tE C Gs h o w ss i m i l a rw a v e f o r m st oh u m a n s[ 49,
50]. As such, mice and rats have greatly diﬀerent sets
of factors for lipoprotein metabolism and cardiovascular
diseases. Therefore, to employ mice and rats for studies on
cardiovascular diseases and lipid metabolism, great care is
requiredwithanalysesand/ortheinterpretationoftheresults
obtained from experiments.
4.TranslationalResearchontheDevelopment
ofthe Lipid-LoweringAgents
Figure 3 shows features of WHHLMI rabbits which resem-
ble humans and applicable translational research ﬁelds.
Since the WHHL rabbit is close to humans in lipoprotein
metabolism, it was used for the development of various
lipid-lowering agents and atherosclerosis-suppressing agents
[8]. The hypolipidemic eﬀects of various drugs have been
investigated with WHHL rabbits (Table 2): cholesterol syn-
thesis inhibitors, such as HMG-CoA reductase inhibitors
and squalene synthetase inhibitors; inhibitors of microsomal
triglyceride transfer protein, which works in the assembly
of VLDL particles in liver; anionic exchange resins, which
block the enterohepatic circulation of bile acids; omega-3
fatty acids, which are a component of ﬁsh oil; ﬁbrates, which
lower serum triglyceride levels. In studies with a cholesterol
synthesis inhibitor, statin, serum total cholesterol levels of
WHHL rabbitswere decreased dose-dependentlyby 10–30%
compared with the control group [37, 39]. The mechanisms
for the reduction in serum cholesterol levels by statins are an
increase in expression of mRNA of LDL receptors in the liver
[39] and, decrease in the excretion of VLDL cholesterol from
theliverincasesofhigh-dose treatment [38]. The agentsthat
inhibit squalene synthetase, another rate-limiting enzyme in
cholesterol synthesis, also decreased the serum cholesterol
level by similar mechanisms [51]. Since a small amount of
LDL receptor protein can be processed from a precursor
to a mature form in WHHL ﬁbroblasts [52], inhibition
of cholesterol synthesis in the liver is expected to cause
LDL receptors to accumulate on the surface of hepatocytes.
Anion exchange resins absorb bile acids at the duodenum
and block the enterohepatic circulation [53]. As a result,
cholesterol is utilized in the hepatocytes for the synthesis of
bile acids, and then the hepatocytes, which was exhausted
the cholesterol pool, increase the number of LDL receptor
molecules to acquire external cholesterol [39]. Therefore, the
combination of an inhibitor for cholesterol synthesis and an
anion exchange resin can decreasetheserum cholesterollevel
markedly, and this was proved using WHHL rabbits [40].
Since microsomal triacylglycerol transfer protein (MTP)
inhibitors are also eﬀective in WHHL rabbits [54], they
may have potential beneﬁt for human FH. The successful
treatment in WHHL rabbits means that patients with FH,
excluding the LDL-receptor negative type, can be treated
with these agents.Journal of Biomedicine and Biotechnology 5
Table 2: Drug development using WHHL/WHHLMI rabbits.
Lipid-lowering eﬀect Lipid-lowering eﬀect
Aorta Coronary arteries
Cholesterol synthesis inhibitors
Statins O X, O O
Squalene synthesis inhibitor O O O
Anion exchanger O O
Statins + Anion exchanger O O O
MTP inhibitor O
A C A Ti n h i b i t o r X ,O X ,O X ,O
Antioxidants
Probucol O O
Vitamin E X X, O
Colony stimulatingfactor
MCSF X, O O
GMCSF X, O O
Apo E X, O O
Fibrate X
Fish oils, ommega-3 fatty acids X, O X, O
Thiazolidinedione X ΔΔ
Thiazolidinedione + statin O O O
Antihypertensive
ACE inhibitor X O
AT-II receptor antagonists X O
Calcium antagonists X X
Beta-blockers X X
Gene therapy O
O: eﬀective; Δ:p a r t l ye ﬀe c t i v e ;X :n oe ﬀect.
Modiﬁed from Shiomi and Ito [8].
Features of WHHLMI rabbits resembling humans
Development and evaluation of
antiatherosclerotic compounds 
Development of
imaging techniques
of atherosclerosis  
Searching for risk factors for
coronary unstable plaques and/or
acute coronary syndromes  
Applicable translational research fields
Development and evaluation of
medical devices for atherosclerosis 
Lipoprotein metabolism and
lipoprotein profile in plasma 
Mechanism of
atherogenesis 
Morphology of
atherosclerotic lesions 
Myocardial
infarction 
Regeneration of myocardial
cells in ischemic ventricle 
Development and evaluation
of hypocholesterolemic
and/or hypolipidemic
compounds or therapeutics
Figure 3: Features of the WHHLMI rabbit resembling humans and applicable translational research ﬁelds.6 Journal of Biomedicine and Biotechnology
5.TranslationalResearchon
AntiatheroscleroticEffects
The purpose of lowering serum cholesterol levels is to
inhibit atherogenesis and to circumvent the cardiovascular
and cerebrovascular events. The WHHL rabbit contributed
to prove the eﬀects of cholesterol-lowering therapies on
delaying the progression of atherosclerosis. Statin treatment
resulted in a decrease in serum total cholesterol levels by
20–30%, and the cross-sectional narrowing of the coronary
arteries was signiﬁcantly decreased [41–45].
In several clinical studies, the incidence of cardiovas-
cular events was signiﬁcantly reduced in the statin-treated
groups despite little or no improvement in coronary stenosis
on evaluation by coronary angiography [55]. The WHHL
rabbit contributed to the clariﬁcation of this paradoxical
mechanism [42–45]. On the administration of statin to 10-
month old WHHL rabbits for one year, in which coronary
atherosclerosis had already developed to a mature stage,
statin treatment showed not only the prevention of further
progression of the coronary atherosclerotic lesions, but
also various stabilizing eﬀects on coronary plaques, such
as reductions in the contents of macrophages and extra
cellular lipids in lesions, and increase in the contents of
collagen ﬁbers and preservation of the smooth muscle cells
in lesions. Thus it was clariﬁed that, statin administration
makes atherosclerotic lesions more stable, that is, less likely
to rupture. With this study, it was conﬁrmed that the
stabilization of atherosclerotic lesions is important for the
prevention of coronary events. Nowadays, more than 40
million patients worldwide are prescribed statins. Another
type of cholesterol synthesis inhibitor, squalene synthesis
inhibitors, that act downstream of the cholesterol synthesis
pathway, also showed similar hypocholesterolemic and athe-
roma-stabilizing eﬀects in WHHLMI rabbits [56].
Using WHHLMI rabbits, antiatherosclerotic eﬀects have
also been evaluated with other compounds such as omega-3
fattyacids,whichdecreaseserumtriglyceridelevelsbychang-
ingthecompositionoffattyacids[57–61];antioxidants,such
as probucol, vitamin C, and vitamin E [62–65]; agents that
regulate the function of macrophages [66, 67]; drugs that
inhibit the rennin-angiotensin pathway [68–71]. Interest-
ingly, antiatherosclerotic eﬀects of antihypertensive agents
were unequal in WHHL or WHHLMI rabbits. Angiotensin
converting enzyme (ACE) inhibitors and angiotensin-II re-
ceptor blockers (ARBs) showed antiatherogenic eﬀects [69–
72], but calcium antagonists and beta-blockers were not
eﬀective [73, 74]. Systolic blood pressure in WHHL and
WHHLMIrabbitsis100–120mmHg,which isslightlyhigher
than normal [75]. This may be why calcium antagonists
and beta-blockers did not show distinct antiatherosclerotic
eﬀects.Incontrast,antihypertensive eﬀectsofACEinhibitors
and ARBs are mediated by suppressing the eﬀects of angiot-
ensin II. Angiotensin-II stimulates atherogenesis by impair-
ing the function of arterial endothelial cells, proliferation of
arterial smooth muscle cells, and inﬂammation [76]. These
pleiotropic eﬀects of angiotensin-II are considered to be
mediated byreactive oxygenspecies. Thus, theWHHLrabbit
is indispensable for studies on the antiatherosclerotic eﬀects
of the various compounds.
6.Imaging Technology forEvaluation
of AtheroscleroticLesions
Although it is important to evaluate drug eﬃcacy in clinical
use, it is diﬃcult to evaluate atheroma-stabilizing eﬀects
of drugs in clinical practice. With coronary angiography,
it is possible to see the degree of stenosis but diﬃcult to
evaluate the severity of lesions, if the lesions are spread and
extended in the coronary arteries, or if the coronary arteries
are expanded due to the outward remodeling of the vessels.
Furthermore, it is very important to develop noninvasive
technologiesandequipmenttodetectdangerouslesions, that
is, vulnerable plaques that are prone to rupture, not only for
the diagnosis butfor the preventionof cardiovascular events.
As vulnerable plaques that cause cardiovascular events, soft-
type plaques rich in macrophages and large lipid droplets
covered with a thin ﬁbrous cap are important. To detect
such soft-type plaques, computed tomography (CT) [77],
positron emission tomography (PET) [77], CT plus PET
[78], magnetic resonance (MRI) [78, 79], and intravascular
ultrasound (IVUS) [80] have been applied to WHHLMI
rabbits. One successful example was evaluation of the an-
tiatherosclerotic eﬀect of probucol, a potent antioxidant, in
WHHLMIrabbitsby imaging with CTplusPET [81].Ogawa
et al. demonstrated clearly that imaging with CT plus PET is
powerful technology to detect antiatherosclerotic eﬀects of
compounds. Once imaging technologies for the evaluation
of atherosclerotic lesions are established, they can be used
not only for the assessment of drug eﬀects, but also for the
detection of dangerous coronary lesions that could lead to
cardiovascular events such as acute coronary syndromes and
consequently the prevention of ischemic heart diseases.
7.Perspectives
To overcome cardiovascular diseases, many research issues
remain unresolved, despite diligent studies for the devel-
opment of diagnostic methods and lipid-lowering agents.
Particularly important is clarifying the mechanism of the
disruption of coronary lesions (arterial plaque rupture and
the following formation of a thrombus), which depress the
trigger for the onset of acute coronary syndromes, and
establishment of treatments. Still no suitable animal model,
which is compatible with the study of human acute coronary
syndromes, has beendeveloped.To developa suitableanimal
model for human acute coronary syndromes, trial stud-
ies/experimentssuch astheenhancementofvulnerablecoro-
nary lesions, and applicationof physicalpressure tocoronary
lesions, are currently underway with WHHLMI rabbits. To
destabilize coronary lesions, serial selective breeding with
new criteria such as the formation of vulnerable plaques is
also ongoing, in parallel with the development of genetically
modiﬁed WHHLMI rabbits overexpressing matrix metallo-
proteinases (MMPs), and so forth. The established strain
would be a subject of analyses for the identiﬁcation ofJournal of Biomedicine and Biotechnology 7
the genes/loci responsible for the phenotype established. In
thenear future,with advances in gene-targeting technologies
by using ES or iPS cells capable of germ-line transmission,
in combination with the nuclear transfer technique, more
precise manipulation of the rabbit genome may also be
available. Since the lesion composition and severity of
coronary lesions diﬀer even in WHHLMI rabbits, despite no
diﬀerencein theserumcholesterol levels,itwill beimportant
to explore marker proteins and/or risk factors aﬀecting
coronary lesions. Once markers and risk factors relating to
vulnerable coronary atheromas are found, the mechanism of
cardiovascular events may be clariﬁed. Such ﬁndings would
contribute to the development of new clinical diagnostics
and thence to the prevention of cardiovascular events.
In conclusion, selecting appropriate animal model is
important in translational research. WHHL and WHHLMI
rabbits have contributed to development of hypocholes-
terolemic and antiatherosclerotic compounds and medical
devices, such as imaging technologies for atherosclerosis,
and diagnostic techniques for acute coronary syndromes, in
addition to elucidation of the mechanisms of atherogenesis
and coronary plaque rupture. These studies are helpful for
progression of therapeutics.
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